Abstract # 52.

"Conclusions: Based on un-adjudicated reports, there appears to be a 3.2-fold risk of lung cancer and 2.3-fold risk of lung cancer mortality among patients randomized to Exubera. There was no evidence of increased risk of all cause mortality."